Benzinga | Nov 4, 2021 09:27AM EDT

Actinium Announces Completion Of Enrollment Of Actimab-A CLAG-M Combination Trial In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Fit For Induction Therapy

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) who are fit for intensive therapy has completed the planned dose escalation and patient enrollment. Patients in the fourth and final dose escalation cohort received 1.0 ?Ci/kg of Actimab-A with the standard CLAG-M dose regimen. This novel combination trial is being conducted at the Medical College of Wisconsin. Updated Phase 1 data is expected will be presented at the American Society of Hematology (ASH) Annual Meeting in December and Actinium expects to provide an update on the future clinical development of this combination by year end.